Ubiquitin

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
Patient, ICB, Neoplasm, Cancer, Ubiquitin, Biology, AACR, Phenotype, Aberrant, MAVS, Autoimmune disease, PD-1, Pharmaceutical industry

AUSTIN, TX and DURHAM, NC, April 09, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data demonstrating the therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy. These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.

Key Points: 
  • These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.
  • Our efforts in helping to define the underlying biology of acquired resistance were recently revealed with a publication in Cancer Cell,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • TRIM7 also contributes to PD-1 acquired resistance through ubiquitination and degradation of STING and MAVS.
  • A copy of the AACR presentation will be available on the Investors section of the Company’s website shortly after the event.

Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Nanna, DUB, UPS, Therapy, Enzyme, Dub, Ubiquitin, Drug discovery, Pharmaceutical industry

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).

Key Points: 
  • Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).
  • Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.
  • Dysregulation of DUB activity is implicated in many human diseases, highlighting their importance and promise for the development of novel therapeutics.
  • Jason Mundin, CEO of Ubiquigent, commented: “We are delighted to enter this latest agreement and look forward to supporting the team at Nanna Therapeutics.

Proxygen Announces Formation of Scientific Advisory Board

Retrieved on: 
Wednesday, November 15, 2023
MSD, DRS, Broad Institute, DNA, Limited partnership, National academy, Dana–Farber Cancer Institute, Patient, Research, Ubiquitin, Pharmacology, Therapy, Chromatin, Pioneer, Drug discovery, Cancer, Diabetes, Harvard University, Field, Howard Hughes Medical Institute, Translation, Organization, MIT, European, Jude the Apostle, Merck & Co., Austrian Academy of Sciences, Max Planck Society, Translational medicine, Leibniz Prize, JDRF, Pancreatic cancer, Ernst Jung Prize, Biochemistry, SAB, EMBO, Publishing, Louis-Jeantet Prize for Medicine, Pharmacia, Glioblastoma, Boehringer Ingelheim, Medicine, Biotechnology, Genomics, Doctor of Philosophy, Monroe Dunaway Anderson, Biology, DNA repair, Pharmaceutical industry, Science, Merck

VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB). The newly appointed SAB, which is comprised of highly regarded thought leaders in the emerging field of protein degradation, will offer scientific expertise and guidance to Proxygen as the company works to advance its internal molecular glue degrader programs toward clinical development. In addition to its internal programs, Proxygen is also actively engaged in strategic research collaboration and license agreements with Merck & Co (known as MSD outside the U.S. and Canada), Boehringer Ingelheim and Merck KGaA designed to jointly identify and develop novel molecular glue degraders.

Key Points: 
  • SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine
    VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB).
  • Schulman and Draetta to the Proxygen team as key advisors and pair them with Drs.
  • Winter and Kubicek, who co-founded the company, based on their trailblazing research at CeMM,” said Bernd Boidol, Ph.D., chief executive officer of Proxygen.
  • By streamlining and fully integrating cutting-edge genomic, proteomic, and biochemical technologies, Proxygen has successfully developed a highly versatile glue degrader discovery engine.

Michael J. Fox Foundation for Parkinson's Research Honors Dario Alessi, PhD, with the Robert A. Pritzker Prize for Leadership in Parkinson's Research

Retrieved on: 
Monday, November 13, 2023
School, Genetics, ASAP, University of Dundee, Research, Phosphorylation, Parkinson's disease, Biology, Alessi, Disease, Science, History, Student, MJFF, Mentorship, Ubiquitin, Pritzker Architecture Prize, University, LRRK2, Doctor of Philosophy, Mutation, Signal transduction, Pharmaceutical industry, PD

The prize recognizes researchers who make exceptional contributions to Parkinson's disease (PD) research and are committed to mentoring the next generation of Parkinson's scientists.

Key Points: 
  • The prize recognizes researchers who make exceptional contributions to Parkinson's disease (PD) research and are committed to mentoring the next generation of Parkinson's scientists.
  • Padmanabhan presented the prize to Alessi at the Foundation's Research Roundtable event in New York City on November 11, 2023.
  • The Robert A. Pritzker Prize for Leadership in Parkinson's Research, awarded annually by MJFF since 2011, was established by Karen Pritzker, daughter of Robert A. Pritzker, and her late husband, investor Michael Vlock.
  • Watch the "Robert A. Pritzker Prize for Leadership in Parkinson's Research: Inspiring Hope for a World Free from Parkinson's" video: https://www.youtube.com/watch?v=KkaefcwfE4Q

Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson's Disease

Retrieved on: 
Monday, November 13, 2023
Parkinson's disease, Research, Alpha-synuclein, Therapy, Pathology, PD, Mouse, Patient, Mission, Dopamine, Ubiquitin, Neuron, Nature Communications, University of Cambridge, Harvard Medical School, Mitochondrion, Human, Death, Disability, Biomarker, Cell, Mitophagy, Pharmaceutical industry, Palladium, Disease

CAMBRIDGE, England, Nov. 13, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled 'Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's Disease (PD) mouse model' in the journal Nature Communications, which can be viewed here. The research was the result of collaborative work between Cambridge University, Harvard Medical School, and Mission Therapeutics.

Key Points: 
  • Mission Therapeutics is a global leader in discovering and developing innovative therapeutics that promote mitophagy.
  • By inhibiting the enzyme USP30, Mission's experimental drug MTX325 helps promote mitochondrial quality control by increasing the removal of dysfunctional mitochondria.
  • Dr Anker Lundemose, Chief Executive Officer at Mission Therapeutics, said: "The exciting findings of this Nature Communications paper are a tremendous boost to Mission's Parkinson's Disease programme.
  • The Nature Communications paper outlines how Mission's drug MTX325 has potential as a novel, disease-modifying treatment for Parkinson's, by enhancing mitophagy and clearing dysfunctional mitochondria.

Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson's Disease

Retrieved on: 
Monday, November 13, 2023
Parkinson's disease, Research, Alpha-synuclein, Therapy, Pathology, PD, Mouse, Patient, Mission, Dopamine, Ubiquitin, Neuron, Nature Communications, University of Cambridge, Harvard Medical School, Mitochondrion, Human, Death, Disability, Biomarker, Cell, Mitophagy, Pharmaceutical industry, Palladium, Disease

CAMBRIDGE, England, Nov. 13, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled 'Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's Disease (PD) mouse model' in the journal Nature Communications, which can be viewed here. The research was the result of collaborative work between Cambridge University, Harvard Medical School, and Mission Therapeutics.

Key Points: 
  • Mission Therapeutics is a global leader in discovering and developing innovative therapeutics that promote mitophagy.
  • By inhibiting the enzyme USP30, Mission's experimental drug MTX325 helps promote mitochondrial quality control by increasing the removal of dysfunctional mitochondria.
  • Dr Anker Lundemose, Chief Executive Officer at Mission Therapeutics, said: "The exciting findings of this Nature Communications paper are a tremendous boost to Mission's Parkinson's Disease programme.
  • The Nature Communications paper outlines how Mission's drug MTX325 has potential as a novel, disease-modifying treatment for Parkinson's, by enhancing mitophagy and clearing dysfunctional mitochondria.

Insights on the Protease Global Market to 2028 - Featuring Associated British Foods, BASF, Dupont De Nemours and Novozymes Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022
Food, Beverage, Retail, Burns, Ubiquitin, Health, Hydrolysis, Stomach, Chronic pain, Food safety, Dub, Inflammatory Bowel Diseases, COVID-19, Virus, Food, Application, Diarrhea, Enzyme, Vomiting, Nausea, World Health Organization, Allergy, Organic acid, Immune system, Proteolysis, Prevalence, WHO, Renewable energy, Fine chemical, Dietary supplement

The Global Protease Market size is expected to reach $5 billion by 2028, rising at a market growth of 5.5% CAGR during the forecast period.

Key Points: 
  • The Global Protease Market size is expected to reach $5 billion by 2028, rising at a market growth of 5.5% CAGR during the forecast period.
  • Proteolysis would occur very slowly, requiring hundreds of years if there were no functional accelerants.
  • Distinct classes of protease can carry out the same reaction by entirely different catalytic processes as a result of their own numerous independent evolutionary cycles.
  • The hydrolysis of peptide bonds is a typical chemical reaction that is effectively carried out by proteases.

4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Retrieved on: 
Tuesday, December 6, 2022
Janus, DUB, Ubiquitin, Enzyme, Capital Markets Board of Turkey, Protein, ENTAC, Qiming Venture Partners, University of Liverpool, Dub, Medicine, Doctor of Philosophy, WEHI, Disease, Therapy, University, Patient, Encompass, Fine chemical, Citadel

The Series A financing follows an initial seed investment from 4BIO Capital and Arkin Bio Ventures who supported and incubated the company.

Key Points: 
  • The Series A financing follows an initial seed investment from 4BIO Capital and Arkin Bio Ventures who supported and incubated the company.
  • With broad utility across disease types, ENTACs have significant potential to expand the druggable space and address unmet medical needs.
  • Many diseases occur when there is a functional problem with a beneficial protein that is critical to cell health.
  • Ubiquitin plays a broad role in protein function, so tailored removal of ubiquitin can enhance the function of the target protein.

Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, Pharmaceutical, Health, Janus, Therapy, Scale Venture Partners, Qiming Venture Partners, Medicine, Enzyme, Doctor of Philosophy, Protein, University of Liverpool, Patient, WEHI, Greve, Buhrlage, and Company, ENTAC, Disease, Ubiquitin, Bio, University, Biochemistry, DUB, Olivier Richon, Encompass, Dub, Fine chemical, Citadel

These ENTAC medicines will make an important difference for patients whose needs aren't adequately met by todays treatments.

Key Points: 
  • These ENTAC medicines will make an important difference for patients whose needs aren't adequately met by todays treatments.
  • Ubiquitin plays a broad role in protein function, so tailored removal of ubiquitin can enhance the function of the target protein.
  • Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins.
  • By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

The Worldwide Epigenetics Industry is Expected to Reach $3.9 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Health, Genetics, Software, Enzyme, Citrullination, Acetylation, Government, USD, Ubiquitin, DNA, Product-service system, DNA methylation, Method, Phosphorylation, CAGR, Methylation, Growth, Video game, Lithium

The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period.

Key Points: 
  • The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period.
  • Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service.
  • This is expected to suffice the significant elevation in the number of epigenetics research activities conducted in the past few years.
  • Additionally, market players are expanding their product offerings around epigenetics antibodies, which is further expected to supplement the segment's dominance.